Progress in the US With Biosimilars, but Opportunities Remain
Last year was a big year for biosimilars in the United States with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place in 2018.\n\nKelly Davio, senior editor of AJMC's The Center for Biosimilars, highlights recent progress, how the US market compares with Europe, and what remains to be seen.\n\nRead more:\nThe Center for Biosimilars: https://www.centerforbiosimilars.com/\nStakeholders Weigh In on the Key Biosimilar Developments of 2018: https://www.centerforbiosimilars.com/news/stakeholders-weigh-in-on-the-key-biosimilar-developments-of-2018\nCoherus Confirms That It Has Launched Its Pegfilgrastim Biosimilar, Udenyca: https://www.centerforbiosimilars.com/news/coherus-confirms-that-it-has-launched-its-pegfilgrastim-biosimilar-udenyca\nFDA Releases Biosimilar Action Plan: https://www.centerforbiosimilars.com/news/fda-releases-biosimilar-action-plan\nPfizer Launches Epoetin Alfa Biosimilar, Retacrit, at 33.5% Discount to Reference Epogen: https://www.centerforbiosimilars.com/news/pfizer-launches-epoetin-alfa-biosimilar-retacrit-at-335-discount-to-reference-epogen\nPfizer Becomes Latest to Settle With AbbVie Over Humira: https://www.centerforbiosimilars.com/news/pfizer-becomes-latest-to-settle-with-abbvie-over-humira